Trump rescinded an executive order that required the Center for Medicare and Medicaid Services (CMS) to develop and test ways to lower drug prices for people on Medicare and Medicaid. Since former-President Joe Biden's 2022 order, CMS had been planning out and preparing to test three models to lower prices. None of them had fully gone into effect. Therefore, current Medicare and Medicaid enrollees will not see their drug prices go up. They will also not see some of the proposed price cuts scheduled to go into effect in the future. Among the executive orders Trump rescinded during his first day of office is Executive Order 14087, which was an October 2022 order by Biden on “Lowering Prescription Drug Costs for Americans.” That executive order directed the Secretary for the Department of Health and Human Services (HHS) to consider and test “new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for beneficiaries enrolled in the Medicare and Medicaid programs.” CMS ultimately selected to test three models with the goal of improving prescription drug affordability and access for beneficiaries. The first proposed model encouraged sponsors of Medicare Part D, which provides prescription coverage to Medicare enrollees, to offer generic drugs for a $2 monthly copay, with a focus on generics targeting common chronic conditions among Medicare beneficiaries. CMS said this pricing was scheduled to begin as early as January 2027. MORE: https://www.wtsp.com/article/news/verify/medicare-verify/trump-rescind-lower-prescription-costs-medicare-medicaid-fact-check/536-7ec27e53-4f0e-4dd3-883d-b5998341968b